Glaucoma: A review of adjunctive therapy and new management strategies

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Glaucoma is a major cause of vision loss throughout the world. Treatment for glaucoma consists of reducing intraocular pressure (IOP) to an acceptable target range to prevent further optic nerve damage. Typically, this involves the selection of a topical IOP-lowering agent. Five major classes of glaucoma medications are presently available for clinical use. These include α-adrenergic agonists, β-adrenergic antagonists (β-blockers), carbonic anhydrase inhibitors (CAIs), cholinergics and prostaglandin analogs (PGAs). Although β-blockers enjoyed great success as first-line glaucoma therapy for many years, recently the PGAs have gained favor as the initial treatment of choice for most patients. Although the PGAs offer robust IOP reduction as monotherapy, a significant number of patients will require an adjunctive agent for adequate IOP control. Recent studies have demonstrated that α-agonists, β-blockers and CAIs can be used safely and effectively as adjunctive therapy for patients being treated with a PGA. Comparison studies are beginning to appear in the literature to help determine which adjunctive agent is the most effective when used in combination with a PGA. Additional IOP-lowering efficacy with adjunctive therapy does have limitations, particularly with the addition of a third or fourth agent. For those patients on maximal tolerated medical therapy who still need additional IOP reduction, other available options include laser trabeculoplasty and filtration surgery.

Original languageEnglish (US)
Pages (from-to)3237-3249
Number of pages13
JournalExpert Opinion on Pharmacotherapy
Volume8
Issue number18
DOIs
StatePublished - Dec 2007

Fingerprint

Synthetic Prostaglandins
Intraocular Pressure
Glaucoma
Carbonic Anhydrase Inhibitors
Adrenergic Antagonists
Therapeutics
Filtering Surgery
Adrenergic Agonists
Trabeculectomy
Laser Therapy
Optic Nerve
Cholinergic Agents

Keywords

  • α-agonist
  • β-blocker
  • carbonic anhydrase inhibitor
  • cholinergics
  • glaucoma
  • intraocular pressure
  • ocular hypertension
  • prostaglandin analog

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Glaucoma : A review of adjunctive therapy and new management strategies. / Whitson, Jess T.

In: Expert Opinion on Pharmacotherapy, Vol. 8, No. 18, 12.2007, p. 3237-3249.

Research output: Contribution to journalArticle

@article{2f0e7578329042489121bebd63f5556d,
title = "Glaucoma: A review of adjunctive therapy and new management strategies",
abstract = "Glaucoma is a major cause of vision loss throughout the world. Treatment for glaucoma consists of reducing intraocular pressure (IOP) to an acceptable target range to prevent further optic nerve damage. Typically, this involves the selection of a topical IOP-lowering agent. Five major classes of glaucoma medications are presently available for clinical use. These include α-adrenergic agonists, β-adrenergic antagonists (β-blockers), carbonic anhydrase inhibitors (CAIs), cholinergics and prostaglandin analogs (PGAs). Although β-blockers enjoyed great success as first-line glaucoma therapy for many years, recently the PGAs have gained favor as the initial treatment of choice for most patients. Although the PGAs offer robust IOP reduction as monotherapy, a significant number of patients will require an adjunctive agent for adequate IOP control. Recent studies have demonstrated that α-agonists, β-blockers and CAIs can be used safely and effectively as adjunctive therapy for patients being treated with a PGA. Comparison studies are beginning to appear in the literature to help determine which adjunctive agent is the most effective when used in combination with a PGA. Additional IOP-lowering efficacy with adjunctive therapy does have limitations, particularly with the addition of a third or fourth agent. For those patients on maximal tolerated medical therapy who still need additional IOP reduction, other available options include laser trabeculoplasty and filtration surgery.",
keywords = "α-agonist, β-blocker, carbonic anhydrase inhibitor, cholinergics, glaucoma, intraocular pressure, ocular hypertension, prostaglandin analog",
author = "Whitson, {Jess T.}",
year = "2007",
month = "12",
doi = "10.1517/14656566.8.18.3237",
language = "English (US)",
volume = "8",
pages = "3237--3249",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "18",

}

TY - JOUR

T1 - Glaucoma

T2 - A review of adjunctive therapy and new management strategies

AU - Whitson, Jess T.

PY - 2007/12

Y1 - 2007/12

N2 - Glaucoma is a major cause of vision loss throughout the world. Treatment for glaucoma consists of reducing intraocular pressure (IOP) to an acceptable target range to prevent further optic nerve damage. Typically, this involves the selection of a topical IOP-lowering agent. Five major classes of glaucoma medications are presently available for clinical use. These include α-adrenergic agonists, β-adrenergic antagonists (β-blockers), carbonic anhydrase inhibitors (CAIs), cholinergics and prostaglandin analogs (PGAs). Although β-blockers enjoyed great success as first-line glaucoma therapy for many years, recently the PGAs have gained favor as the initial treatment of choice for most patients. Although the PGAs offer robust IOP reduction as monotherapy, a significant number of patients will require an adjunctive agent for adequate IOP control. Recent studies have demonstrated that α-agonists, β-blockers and CAIs can be used safely and effectively as adjunctive therapy for patients being treated with a PGA. Comparison studies are beginning to appear in the literature to help determine which adjunctive agent is the most effective when used in combination with a PGA. Additional IOP-lowering efficacy with adjunctive therapy does have limitations, particularly with the addition of a third or fourth agent. For those patients on maximal tolerated medical therapy who still need additional IOP reduction, other available options include laser trabeculoplasty and filtration surgery.

AB - Glaucoma is a major cause of vision loss throughout the world. Treatment for glaucoma consists of reducing intraocular pressure (IOP) to an acceptable target range to prevent further optic nerve damage. Typically, this involves the selection of a topical IOP-lowering agent. Five major classes of glaucoma medications are presently available for clinical use. These include α-adrenergic agonists, β-adrenergic antagonists (β-blockers), carbonic anhydrase inhibitors (CAIs), cholinergics and prostaglandin analogs (PGAs). Although β-blockers enjoyed great success as first-line glaucoma therapy for many years, recently the PGAs have gained favor as the initial treatment of choice for most patients. Although the PGAs offer robust IOP reduction as monotherapy, a significant number of patients will require an adjunctive agent for adequate IOP control. Recent studies have demonstrated that α-agonists, β-blockers and CAIs can be used safely and effectively as adjunctive therapy for patients being treated with a PGA. Comparison studies are beginning to appear in the literature to help determine which adjunctive agent is the most effective when used in combination with a PGA. Additional IOP-lowering efficacy with adjunctive therapy does have limitations, particularly with the addition of a third or fourth agent. For those patients on maximal tolerated medical therapy who still need additional IOP reduction, other available options include laser trabeculoplasty and filtration surgery.

KW - α-agonist

KW - β-blocker

KW - carbonic anhydrase inhibitor

KW - cholinergics

KW - glaucoma

KW - intraocular pressure

KW - ocular hypertension

KW - prostaglandin analog

UR - http://www.scopus.com/inward/record.url?scp=40949133026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949133026&partnerID=8YFLogxK

U2 - 10.1517/14656566.8.18.3237

DO - 10.1517/14656566.8.18.3237

M3 - Article

C2 - 18035966

AN - SCOPUS:40949133026

VL - 8

SP - 3237

EP - 3249

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 18

ER -